Atonal homolog 1 (ATOH1) (ATOH1)

Atonal homolog 1 (ATOH1) is a basic helix-loop-helix (bHLH) transcription factor that serves as a master regulator of cell fate and differentiation in several tissues, including the inner ear, intestinal epithelium, and cerebellum [1, 15, 18]. It functions by binding to E-box DNA motifs to activate the expression of genes essential for the development of sensory hair cells, intestinal secretory cells (such as Paneth and goblet cells), and specific neuronal populations [13, 14, 19]. In the context of human disease, ATOH1 plays a dual role: it acts as a tumor suppressor in colorectal cancer, where its loss is associated with increased proliferation, but functions as an oncogene in medulloblastoma and certain subtypes of small cell lung cancer [2, 3, 6, 12]. Therapeutically, ATOH1 is a primary target for regenerative medicine aimed at treating sensorineural hearing loss. Gene therapy approaches, such as the clinical candidate CGF166, utilize viral vectors to deliver the ATOH1 gene into the cochlea to induce the transdifferentiation of supporting cells into functional hair cells [5, 7, 10]. Additionally, pharmacological modulation of upstream pathways, particularly the inhibition of Notch signaling via gamma-secretase inhibitors like LY3056480, is explored to indirectly upregulate ATOH1 and promote tissue regeneration [19, 21]. Despite its promise, therapeutic application faces challenges regarding the precise control of expression levels and the potential for oncogenic transformation if misexpressed [7, 18].

Other names

Math1Hath1BHLHA14ATH1Class A basic helix-loop-helix protein 14Helix-loop-helix protein hATH-1

Gene therapy-mediated ectopic expression to induce hair cell regeneration; indirect upregulation via Notch signaling inhibition (gamma-secretase inhibitors) to promote cellular transdifferentiation.